期刊
NATURE MEDICINE
卷 26, 期 2, 页码 171-177出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-019-0736-4
关键词
-
资金
- Cancer Research Institute
- Chan Zuckerberg Initiative
- HHMI International Scholar award
- Merck KGaA, Darmstadt, Germany
- European Research Council Consolidator Grant (ERC-COG) [724471-HemTree2.0]
- Thompson Family Foundation
- MRA Established Investigator Award [509044]
- Eden and Steven Romick Professorial Chair and Eden and Steven Romick Post-Doctoral Fellowship Fund
- Israel Science Foundation [703/15]
- Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine
- Helen and Martin Kimmel award for innovative investigation
- NeuroMac DFG/Transregional Collaborative Research Center Grant
- International Progressive MS Alliance/NMSS [PA-1604-08459]
- Adelis Foundation grant
- Teva Pharmaceutical Industries research grant
- Rising Tide Translation Cancer Research Fund
- Melanoma Research Alliance (MRA) Young Investigator Award
- Israel Cancer Research Fund (ICRF) Research Career Development Award
- Israel Cancer Association Research Grant
- Mizutani Foundation for Glycoscience
- Emerson Collective Cancer Research Fund
- Israel Science Foundation (ISF) Individual Research Grant
- Moross Integrated Cancer Center, a Harry J. Lloyd Trust Career Development Award
- Flight Attendant Medical Research Institute (FAMRI) Research Grants
- Ira and Diana Riklis Fund for CAR-T Therapy
- Enoch Foundation
- Pearl Welinsky Merlo Foundation
- Benoziyo Fund for the Advancement of Science
- Gerty Schwarz Schaier
Recent progress in single-cell genomics urges its application in drug development, particularly of cancer immunotherapies. Current immunotherapy pipelines are focused on functional outcome and simple cellular and molecular readouts. A thorough mechanistic understanding of the cells and pathways targeted by immunotherapy agents is lacking, which limits the success rate of clinical trials. A large leap forward can be made if the immunotherapy target cells and pathways are characterized at high resolution before and after treatment, in clinical cohorts and model systems. This will enable rapid development of effective immunotherapies and data-driven design of synergistic drug combinations. In this Perspective, we discuss how emerging single-cell genomic technologies can serve as an engine for target identification and drug development. Amit and colleagues discuss where single-cell genomic technologies can be applied both in trial design and in the clinical trial stage to improve the development of immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据